Table 3.
Frequency and characteristics of local side effects of the Algerian population.
| Variable | Booster Vaccine Type | Sig. | |||
|---|---|---|---|---|---|
| Adenoviral-Vector-Virus | Inactivated-Virus | Total | |||
| Local side effects | Injection-site pain | 54 (52.9) | 25 (26.6) | 70 (40.3) | 0.000 |
| Arm pain | 20 (19.6) | 12 (12.8) | 32 (16.3) | 0.195 | |
| Heat at the injection site | 26 (25.5) | 16 (17) | 42 (21.4) | 0.149 | |
| Injection-site itching and induration | 11 (10.8) | 6 (6.4) | 17 (8.7) | 0.274 * | |
| Redness | 18 (17.6) | 7 (7.4) | 25 (12.8) | 0.032 | |
| Swelling | 10 (9.8) | 3 (2.1) | 12 (6.1) | 0.052 * | |
| Onset | <12 h | 58 (75.3) | 29 (70.7) | 87 (73.7) | 0.589 |
| >12 h | 10 (13) | 10 (24.4) | 20 (16.9) | 0.129 * | |
| >24 h | 9 (11.7) | 2 (4.9) | 11 (9.3) | 0.327 * | |
| Duration | Less than 24 h | 27 (34.2) | 12 (30) | 39 (32.8) | 0.647 |
| From 24 to 72 h | 30 (38) | 13 (32.5) | 43 (36.1) | 0.557 | |
| From 3 days to a week | 15(19) | 7 (17.5) | 22 (18.5) | 1 * | |
| More than a week | 7 (8.9) | 8 (20) | 15 (12.6) | 0.141 * | |
| Similarity | Not the same signs | 45 (53.6) | 21 (40.4) | 66 (48.5) | 0.135 |
| The same signs as the first dose | 19 (22.6) | 15 (28.8) | 34 (25) | 0.415 | |
| The same signs as the second dose | 2 (2.4) | 5 (9.6) | 7 (5.1) | 0.106 * | |
| The same signs as the two primer doses | 19 (21.4) | 11 (21.2) | 29 (21.3) | 0.970 | |
| Severity | The same severity as the two primer doses | 20 (25.6) | 19 (38.8) | 39 (30.7) | 0.118 |
| Less severe than the two primer doses | 24 (30.8) | 17 (34.7) | 41 (32.3) | 0.645 | |
| More severe than the two primer doses | 34 (43.6) | 13 (26.5) | 47 (37) | 0.052 | |
Chi-squared (χ2) and Fisher (*) tests were used with a significance level (sig.) of 0.05. Bold character refers to statistically significant values.